
Opinion|Videos|January 29, 2025
Best Practices in Switching PBC Therapies
Panelists discuss how clinicians may transition patients to newer agents due to factors such as inadequate biochemical response, tolerability issues (particularly pruritus), or patient preference, while carefully considering the need for washout periods based on each drug's pharmacokinetics and mechanism of action.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some reasons why clinicians may consider a transition from obeticholic acid to seladelpar or elafibranor for PBC?
- Given the different mechanisms of action of obeticholic acid, seladelpar, and elafibranor, what factors should be considered in determining the need for a washout period between treatments vs direct transition?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5

















































































































